The host STING pathway at the interface of cancer and immunity

Journal of Clinical Investigation

Volumn 126, Issue 7, 2016, Pages 2404-2411

  Corrales, Leticia ^a   McWhirter, Sarah M ^b   Dubensky, Thomas W ^b   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Aduro BioTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; AGENTS AFFECTING PROTEIN METABOLISM; ANTINEOPLASTIC AGENT; BETA INTERFERON; DNA; IMMUNOMODULATING AGENT; STING PROTEIN; STING PROTEIN AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; INTERFERON;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLS BY BODY ANATOMY; CYTOKINE PRODUCTION; CYTOSOL; DENDRITIC CELL; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STING PATHWAY; T LYMPHOCYTE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CYTOLOGY; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYTOSOL; DENDRITIC CELLS; DNA, NEOPLASM; HUMANS; IMMUNITY, INNATE; INTERFERON-BETA; INTERFERONS; MICE; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84978419964     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86892     Document Type: Review

References (92)

1. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011; 34 (5):637-650.
2. Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity. 2011; 34 (5):651-664.
3. Elinav E, Strowig T, Henao-Mejia J, Flavell RA. Regulation of the antimicrobial response by NLR proteins. Immunity. 2011; 34 (5):665-679.
4. Loo YM, Gale M Jr. Immune signaling by RIG-Ilike receptors. Immunity. 2011; 34 (5):680-692.
5. Barber GN STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014; 35 (2):88-93.
6. + dendritic cells. J Exp Med. 2011; 208 (10):2005-2016.
7. Woo SR, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014; 41 (5):830-842.
8. Corrales L, et al. Direct Activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015; 11 (7):1018-1030.
9. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010; 16 (4):399-403.
10. + T-cell recruitment. Cancer Res. 2009; 69 (7):3077-3085.
11. Ulloa-Montoya F, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immuno therapy. J Clin Oncol. 2013; 31 (19):2388-2395.
12. Erdag G, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012; 72 (5):1070-1080.
13. Joseph RW, et al. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother. 2012; 35 (9):711-715.
14. Hamid O, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011; 9:204.
15. Ji RR, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012; 61 (7):1019-1031.
16. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366 (26):2443-2454.
17. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 (+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014; 2:3.
18. Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515 (7528):568-571.
19. Azimi F, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012; 30 (21):2678-2683.
20. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313 (5795):1960-1964.
21. +lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29 (15):1949-1955.
22. Rusakiewicz S, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013; 73 (12):3499-3510.
23. Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348 (3):203-213.
24. Valmori D, Lienard D, Waanders G, Rimoldi D, Cerottini JC, Romero P. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res. 1997; 57 (4):735-741.
25. Robbins PF, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013; 19 (6):747-752.
26. Rizvi NA, et al. Cancer immunology. Science. 2015; 348 (6230):124-128.
27. Sistigu A, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20 (11):1301-1309.
28. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15 (7):405-414.
29. Dunn GP, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005; 6 (7):722-729.
30. Diamond MS, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011; 208 (10):1989-2003.
31. + dendritic cells in cytotoxic T cell immunity. Science. 2008; 322 (5904):1097-1100.
32. Bidwell BN, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012; 18 (8):1224-1231.
33. Savitsky D, Tamura T, Yanai H, Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother. 2010; 59 (4):489-510.
34. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008; 134 (4):587-598.
35. Lau L, Gray EE, Brunette RL, Stetson DB. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science. 2015; 350 (6260):568-571.
36. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010; 10 (12):878-889.
37. Diaz MO, et al. Homozygous deletion of the α-and β1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A. 1988; 85 (14):5259-5263.
38. Olopade OI, et al. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res. 1992; 52 (9):2523-2529.
39. Demaria O, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2015; 112 (50):15408-15413.
40. Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A. 2012; 109 (47):19386-19391.
41. Rongvaux A, et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell. 2014; 159 (7):1563-1577.
42. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I inter-feron-dependent innate immunity. Nature. 2009; 461 (7265):788-792.
43. Liu S, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 2015; 347 (6227):aaa2630.
44. Burdette DL, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011; 478 (7370):515-518.
45. Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013; 14 (1):19-26.
46. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008; 455 (7213):674-678.
47. Dempsey A, Bowie AG. Innate immune recognition of DNA: A recent history. Virology. 2015; 479-480:146-152.
48. Romling U, Galperin MY, Gomelsky M. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol Mol Biol Rev. 2013; 77 (1):1-52.
49. McWhirter SM, et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med. 2009; 206 (9):1899-1911.
50. Wu J, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013; 339 (6121):826-830.
51. Diner EJ, et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep. 2013; 3 (5):1355-1361.
52. Gao P, et al. Cyclic [G (2', 5')pA (3', 5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell. 2013; 153 (5):1094-1107.
53. Ablasser A, et al. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013; 498 (7454):380-384.
54. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMPAMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013; 339 (6121):786-791.
55. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science. 2013; 341 (6152):1390-1394.
56. Molinero LL, et al. Epidermal Langerhans cells promote skin allograft rejection in mice with NF-κB-impaired T cells. Am J Transplant. 2008; 8 (1):21-31.
57. Ahn J, Konno H, Barber GN. Diverse roles of STING-dependent signaling on the development of cancer. Oncogene. 2015; 34 (41):5302-5308.
58. Zhu Q, et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol. 2014; 193 (10):4779-4782.
59. Huber S, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 2012; 491 (7423):259-263.
60. Salcedo R, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med. 2010; 207 (8):1625-1636.
61. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9 (11):798-809.
62. Sauer JD, et al. The N-ethyl-N-nitrosoureainduced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun. 2011; 79 (2):688-694.
63. Ohkuri T, et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014; 2 (12):1199-1208.
64. Klarquist J, Hennies CM, Lehn MA, Reboulet RA, Feau S, Janssen EM. STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J Immunol. 2014; 193 (12):6124-6134.
65. Ahn J, Xia T, Konno H, Konno K, Ruiz P, Barber GN. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun. 2014; 5:5166.
66. Barber GN STING: infection, inflammation and cancer. Nat Rev Immunol. 2015; 15 (12):760-770.
67. Lemos H, Huang L, McGaha TL, Mellor AL. Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur J Immunol. 2014; 44 (10):2847-2853.
68. Huang L, et al. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J Immunol. 2013; 191 (7):3509-3513.
69. Lemos H, et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 2016; 76 (8):2076-2081.
70. Poltorak A, Larkin B, Surpris G, Ilyuha V. The role of STING in T lymphocytes (IRM5P). J Immunol. 2015; 194 (1 suppl):59. 8.
71. Xia T, Konno H, Ahn J, Barber GN. Deregulation of STING signaling in colorectal carcinoma donstrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 2016; 14 (2):282-297.
72. Hartlova A, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity. 2015; 42 (2):332-343.
73. Deng L, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014; 41 (5):843-852.
74. Baguley BC, Ching LM. Immunomodulatory actions of xanthenone anticancer agents. Bio Drugs. 1997; 8 (2):119-127.
75. Conlon J, et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid. J Immunol. 2013; 190 (10):5216-5225.
76. Gao P, et al. Structure-function analysis of STING activation by c[G (2', 5')pA (3', 5')p] and targeting by antiviral DMXAA. Cell. 2013; 154 (4):748-762.
77. Kim S, Li L, Maliga Z, Yin Q, Wu H, Mitchison TJ. Anticancer flavonoids are mouse-selective STING agonists. ACS Chem Biol. 2013; 8 (7):1396-1401.
78. Prantner D, et al. 5, 6-Dimethylxanthenone4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem. 2012; 287 (47):39776-39788.
79. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5, 6-Dimethylxanthenone-4-acetic acid. Br J Cancer. 2002; 86 (12):1937-1942.
80. Moilanen E, Thomsen LL, Miles DW, Happer field DW, Knowles RG, Moncada S. Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5, 6-dimethylxanthenone-4-acetic acid. Br J Cancer. 1998; 77 (3):426-433.
81. Sun J, et al. Activation of mitogen-activated protein kinases by 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation. Biochem Pharmacol. 2011; 82 (9):1175-1185.
82. Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014; 9 (6):e99988.
83. Baird JR, et al. Radiotherapy Combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 2016; 76 (1):50-61.
84. Lara PN Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29 (22):2965-2971.
85. Chandra D, et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res. 2014; 2 (9):901-910.
86. Fu J, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015; 7 (283):283ra252.
87. Yi G, Brendel VP, Shu C, Li P, Palanathan S, Cheng Kao C. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One. 2013; 8 (10):e77846.
88. Li T, et al. Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. Sci Rep. 2016; 6:19049.
89. Brody JD, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010; 28 (28):4324-4332.
90. Caskey M, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011; 208 (12):2357-2366.
91. Dowling DJ, et al. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS One. 2013; 8 (3):e58164.
92. Harrington KJ, et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015; 15 (12):1389-1403.